Skip to main content

Table 3 DSS, DMS, RQLQ(S) scores* and percent well days during the grass pollen season

From: A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma

  Placebo (n = 166) Grass AIT (n = 163) Difference 95% CI for difference P value
DSS, mean (SE) 6.06 (.40) 5.69 (.39) -0.37 [-0.41; 1.16] 0.3475
DMS, mean (SE) 1.47 (.22) 1.07 (.20) -0.40 [-0.05; 0.85] 0.0827
RQLQ(S)† score, mean (SE) 1.44 (.12) 1.36 (.12) -0.08 [-0.16; 0.32] 0.5293
Percent well days, mean (SE) 26.03 (3.13) 27.44 (3.29) 1.42 [-8.56; 5.73] 0.6965
  1. *Scores were adjusted using the analysis of variance (ANOVA) model, with treatment group as fixed effect and pollen region as random effect. †RQLQ(S): number of observations: placebo = 840, Grass AIT = 801. AIT Allergy immunotherapy tablet, CI Confidence interval, DMS Daily medication score, DSS Daily symptom score, RQLQ(S) Rhinoconjunctivitis quality of life questionnaire with standardized activities, SE Standard error.